Cerity Partners’s Fulgent Genetics FLGT Stock Holding History

Cerity Partners’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-5,723	Closed	-$312K	–	1202
2022 Q2	$312K	Sell	5,723 -111	-2%	-$6.1K	﹤0.01%	896
2022 Q1	$364K	Sell	5,834 -203	-3%	-$13.4K	0.01%	672
2021 Q4	$607K	Buy	6,037 +360	+6%	+$31.6K	0.01%	541
2021 Q3	$511K	Buy	5,677 +20	+0.4%	+$1.82K	0.01%	460
2021 Q2	$522K	Sell	5,657 -120	-2%	-$9.58K	0.01%	460
2021 Q1	$558K	Buy	+5,777	New	+$596K	0.01%	428

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cerity Partners's FLGT Position: Q3 2022 in Review

Cerity Partners sold out of Fulgent Genetics (FLGT) in Q3 2022, closing a stake of 5,723 shares — an estimated $312K sold.

Cerity Partners first reported a position in FLGT in Q1 2021 and held it in 6 quarters. The position peaked at $607K in Q4 2021. 235 funds tracked by Wall St. Rank hold FLGT as of Q3 2022.

Cerity Partners reported no remaining Fulgent Genetics position as of Q3 2022 after selling out during the quarter.
Cerity Partners sold 5,723 Fulgent Genetics shares in Q3 2022, an estimated $312K.
Cerity Partners first reported a position in Fulgent Genetics in Q1 2021 and held it in 6 quarters.
Cerity Partners's Fulgent Genetics position peaked at $607K in Q4 2021.
235 funds tracked by Wall St. Rank held Fulgent Genetics as of Q3 2022.

Based on Cerity Partners's 13F filing for Q3 2022, filed 14 Nov 2022.